---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-029040"
form_type: "8-K"
ticker: "CRNX"
cik: "0001658247"
company_name: "Crinetics Pharmaceuticals, Inc."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T02:10:39.175337+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Crinetics reports FY2024 net loss $298.4M; cash $1.4B; paltusotine PDUFA Sept 25, 2025

## Summary
- Net loss Q4 2024: $80.6M vs $60.1M YoY; full year $298.4M vs $214.5M.
- Revenue fell to $1.0M in 2024 from $4.0M in 2023; no Q4 revenue.
- Cash $1.4B at Dec 31, 2024, up from $558.6M; includes $925M in equity financings.
- PDUFA target action date for paltusotine (acromegaly) set for Sept 25, 2025.
- Plan to start Phase 3 paltusotine in carcinoid syndrome Q2 2025 and four IND filings in 2025.

## SEC filing metadata
- accession: 0000950170-25-029040
- form_type: 8-K
- ticker: CRNX
- cik: 0001658247
- company_name: Crinetics Pharmaceuticals, Inc.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658247/000095017025029040/0000950170-25-029040-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658247/000095017025029040/crnx-20250227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-029040
- JSON: https://secwatch.observer/filing/0000950170-25-029040.json
- Plain text: https://secwatch.observer/filing/0000950170-25-029040.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.